ABSTRACT
Background: Immune thrombocytopenia (ITP) has been reported following COVID-19 vaccination. After index case fatalities, there was concern among patients both with and without a prior history of ITP in Australia. Objectives: To describe treatment outcomes of ITP after COVID-19 vaccination and compare relapsed vs historical pre-COVID-19 ITP cohorts. Methods: We collected ITP cases in Australia within 6 weeks of receiving any COVID-19 vaccination as part of primary vaccination (up to October 17, 2021). Second, we reviewed platelet charts in a historical ITP cohort to determine whether platelet variability was distinct from relapsed ITP after vaccination. Results: We report on 50 patients (37 de novo, 13 relapsed ITP) vaccinated from March 22, 2021, to October 17, 2021. Although there was 1 fatality, bleeding was otherwise mostly minor: (70% WHO bleeding grade <2). De novo ITP was more likely after AstraZeneca ChAdOx1 nCoV-19 (89%) than Pfizer BNT162b2 (11%). Most patients responded quickly (median, 4 days; complete response, 40 of 45 [89%]). In the historical cohort, only 6 of 47 patients exhibited platelet variability (>50% decrease and platelets <100 × 109/L), but median platelet nadir was significantly higher than vaccination relapse (27 vs 6 × 109/L, P =.005). Conclusion: ITP was more frequently reported after AstraZeneca ChAdOx1 nCoV-19 than Pfizer BNT162b2 vaccination. Standard ITP treatments remain highly effective for de novo and relapsed ITP (96%). Although thrombocytopenia can be severe after vaccination, bleeding is usually mild. Despite some sampling bias, our data do not support a change in treatment strategies for patients with ITP after vaccination.
ABSTRACT
This editorial is written at an unprecedented time in human history, when the entire world is engulfed with the effects of COVID-19 pandemic. The pandemic has taken lives of millions of people, destroyed families, and disrupted the livelihoods of hundreds of millions more. Isolations, lockdowns, and restricted movements threaten to hamper business and unravel the social fabric of the contemporary world. With widespread movement restrictions, human resilience is put to the test, manifesting through the digitalization of businesses, governments, and societies. Consequently, digital business transformation can be conceived as the single most important force to thrive in an exceptional time. In this special issue, we include seven insightful and well-executed research articles that advances contemporary knowledge on digital business transformation in the domains of innovation and entrepreneurship. We believe that these articles are only pertinent to the current circumstances where innovation and entrepreneurship are inevitably digitally-driven, but they are also likely to be relevant beyond the pandemic where digitalization would become the new norm in business transformation.
ABSTRACT
In the management of the global COVID-19 pandemic, the mandated closure of workplaces and stay-at-home orders have forced workers to adapt to a prolonged period of unplanned telecommuting, which we term epidemic-induced telecommuting. Although epidemic-induced telecommuting has drastically altered how work is conducted, scant attention is being paid to this emerging work arrangement. To this end, we combine psychological reactance theory and person-environment fit theory to advance the concept of misfit between worker and environment as a core determinant of employees' work experience in the epidemic-induced telecommuting. Particularly, we distinguish between supply-value and demand-ability misfits as constraints on workers' freedom at work. Having analyzed data collected through a survey administered on remote workers, we discovered that both misfits positively influenced workers' perceived psychological reactance, which led to work exhaustion and counter-productive behaviors. We also found that the utilization of collaborative technologies moderated the effects of misfit on workers' psychological reactance.